echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Nature review: NK cells fight cancer, these development directions deserve attention

    Nature review: NK cells fight cancer, these development directions deserve attention

    • Last Update: 2022-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎WuXi AppTec Content Team Editor Natural Killer (NK) cells are innate lymphocytes that have the ability to find and rapidly kill infected, cancerous, foreign or stressed cells

    .

    NK cells have received extensive attention in recent years.
    They can not only directly kill tumor cells, but also rapidly express a variety of cytokines and chemokines, recruit other immune cells and promote adaptive immune responses of T cells and B cells

    .

    Moreover, NK cells can be activated by IgG antibodies, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC)
    .

    In addition, it rarely stimulates an autoimmune response, but instead promotes immune balance and fights autoimmune diseases
    .

    The various beneficial characteristics of NK cells make them ideal targets for immunotherapy
    .

    A recent review in Nature Reviews Drug Discovery took stock of multiple strategies for using NK cells to develop anticancer immunotherapies
    .

    The biology of human NK cells NK cells belong to type 1 innate lymphocytes, and one of its main characteristics is the production of type 1 cytokines, including IFNγ and tumor necrosis factor (TNF)
    .

    The activity of NK cells is regulated by a variety of activating and inhibitory receptors expressed on the cell surface
    .

    Most healthy cells express the major histocompatibility complex type I (MHC-I), which stimulates potent inhibitory signals to suppress NK cell activity
    .

    While tumor cells often evade recognition by CD8-positive cytotoxic T cells by reducing MHC-I expression, loss of MHC-I ligands and/or increased expression of activating receptor ligands alter signaling pathways within NK cells balance, causing NK cells to activate and attack target cells with which they come into contact
    .

    ▲The mechanism of action of NK cells (Image source: Reference [2]) In peripheral blood, NK cells can easily contact blood tumor cells, and solid tumors are relatively difficult to reach and infiltrate, and they have immunosuppressive ability.
    The tumor microenvironment can drive NK cells into an exhausted state

    .

    Currently, researchers are using a variety of means to enhance the function of NK cells
    .

    Strategies to Enhance NK Cell Function Cytokines that Stimulate NK Cells Antagonists of various activating or inhibitory cytokines are currently being evaluated in clinical trials
    .

    For example, IL-2 can directly stimulate the proliferation and activation of T cells and NK cells
    .

    IL-2 is frequently used to activate NK cells in vitro, however its use in vivo is limited by toxic side effects and activation of immunosuppressive regulatory T cells (Treg)
    .

    Several companies are developing IL-2 analogs that selectively activate T cells and NK cells
    .

    For example, SAR444245 of Sanofi, nemvaleukin alfa (ALKS 4230) developed by Alkermes, ANV419, a selective IL-2R agonist developed by Anaveon, and so on
    .

    Related reading: Nature review: Four strategies for the treatment of cancer and autoimmune diseases, transforming IL-2 IL-15 is one of the cytokines that is expected to replace the function of IL-2.
    It can stimulate NK and CD8 positive T cells, but does not activate Treg cells

    .

    Currently, several IL-15 recombinant proteins are being tested in clinical trials
    .

    Among them, ImmunityBio's IL-15 super agonist Anktiva (N-803) has achieved positive results in clinical trials for the treatment of bladder cancer, indolent non-Hodgkin's lymphoma and other diseases
    .

    ▲ The mechanism of action of Anktiva (Image source: ImmunityBio's official website) Other cytokines that activate NK cells include IL-12, IL-18, IL-21, and TGFβ inhibitors
    .

    A typical effector function of antibody NK cells that elicit an ADCC response is the killing of cells targeted by IgG1 or IgG3 antibodies through CD16 receptor-mediated ADCC
    .

    The different morphology of CD16 on the surface of NK cells affects the affinity of CD16 with the Fc-terminal of the antibody
    .

    Specifically, when the amino acid at position 158 of the CD16 protein is phenylalanine (158F), the affinity for Fc is low, and when the amino acid at this position is valine (158V), the affinity for Fc is high
    .

    Many of the new generation of monoclonal antibody therapies have modified the Fc-terminal to improve their binding to CD16 and promote ADCC production
    .

    At the same time, many antibodies were synthesized using a mammalian culture system that prevented fucosylation of the Fc terminal of the antibody, which enhanced their binding to CD16
    .

    Bispecific or Trispecific Antibodies Bispecific or trispecific antibodies can simultaneously bind to receptors that activate NK cells and tumor antigens, promoting more potent and durable NK-mediated cytotoxicity
    .

    Unlike common mAbs, these fusion proteins can be designed to bind to a variety of tumor antigens and NK receptors, and can utilize antibody variable region fragments (Fv) to bind to CD16, ensuring that they can bind to 158V C16 and 158F C16 binds efficiently
    .

    Similar protein designs have been used in bispecific T cell engagers (BiTEs)
    .

    Currently, one of the most rapidly advancing CD16 bispecific antibodies is AFM13 developed by Affimed
    .

    This is a bispecific antibody targeting CD30
    .

    In a phase 1 clinical trial in patients with Hodgkin and non-Hodgkin lymphoma, it was combined with cord blood-derived NK cells to achieve a 100% objective response rate in 12 patients treated at the recommended dose
    .

    Trispecific NK cell adapters can not only bind to tumor antigens and CD16 receptors, but also contain IL-15, thereby enhancing NK cell activity by binding to IL-15 receptors on the surface of NK cells
    .

    Trispecific antibodies are emerging as an exciting frontier in NK cell immunotherapy due to their potential to simultaneously bind to different NK cell receptors
    .

    However, which activating receptor combinations can maximize the anticancer activity of NK cells still requires more research
    .

    ▲Bispecific and trispecific antibodies that enhance NK cell function (Image source: Reference [1]) Adoptive NK cell therapy Most adoptive NK cell therapies collect NK cells through different channels and enhance their functions in vitro.
    They are then infused into cancer patients

    .

    Both autologous and allogeneic NK cells can be used as a source of adoptive NK cell therapy
    .

    There are various sources of allogeneic NK cells, including peripheral blood NK cells, NK cells from umbilical cord blood or placenta, and NK cells differentiated from induced pluripotent stem cells (iPSCs)
    .

    Some studies have shown that NK cells derived from umbilical cord blood are easier to culture and activate, but NK cells obtained from adult peripheral blood have a more natural cytolytic capacity
    .

    NK cell lines (such as NK92) and iPSC cell lines may provide a source of NK cells that can be regenerated repeatedly
    .

    ▲Different sources of NK cells (Image source: Reference [3]) In terms of enhancing the function of NK cells, a straightforward approach is to use cytokines for stimulation in vitro, and the historically commonly used cytokine is IL-2
    .

    In recent years, other stimulatory factors such as IL-12, IL-15, IL-18, and IL-21 have also been used to stimulate NK cells in vitro, and can generate NK cells with long-term survival and memory ability
    .

    The CD16/CD30-targeting bispecific antibody AFM13 developed by Affimed can also be used to pre-bind with NK cells in vitro to promote NK cell responses to CD30-positive lymphomas
    .

    Today, Affimed announced the latest clinical trial results of AFM13 at the AACR conference
    .

    For details, please see today's post
    .

    Expression of chimeric antigen receptors (CARs) targeting tumor antigens on the surface of NK cells can confer the ability of NK cells to target specific tumors
    .

    CAR-NK cells may offer several advantages over CAR-T cells, including a lower risk of cytokine release syndrome
    .

    And even if CAR-NK cells lose CAR, they can still recognize and kill tumor cells through intrinsically expressed activating receptors
    .

    In addition to the introduction of CAR, researchers are exploring other strategies for genetic engineering to enhance NK cell function
    .

    These include promoting tumor infiltration by expressing chemokine receptors
    .

    ADCC-based therapy can express the high-affinity 138V CD16 receptor on NK cells and combine with antibodies that stimulate ADCC to constitute combination therapy
    .

    Finally, side-regulators can be knocked out from NK cells using the CRISPR-Cas9 gene editing system
    .

    These approaches offer multiple possibilities for building better NK cell therapies
    .

    ▲Part of the adoptive NK cell therapy in the clinical development stage (data source: reference [1], WuXi AppTec content team drawing) summary and future direction review The author pointed out that although the development of NK cells as anti-cancer immunotherapy has gained rapid momentum in recent years.
    The development of this field is still in its infancy, and the future of developing new approaches to further enhance NK cell immunotherapy platforms looks bright

    .

    Important goals to be addressed include improving the targeting specificity of NK cells to solid tumors and how to enhance their activation, cytolytic capacity, and survival when NK cells reach an immunosuppressive tumor microenvironment
    .

    CARs, advanced antibody engineering, and multiple receptor binding technologies offer a wide range of opportunities to optimize NK cell activation
    .

    Combination therapies focused on NK cells will provide the next wave of clinical advances
    .

    Reference: [1] Maskalenko et al.
    , (2022).
    Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.
    Nature Reviews Drug Discovery, https://doi.
    org/10.
    1038/s41573-022-00413-7 [2] Le Saux and Schvartzman (2019).
    Advanced Materials and Devices for the Regulation and Study of NK Cells.
    Int.
    J.
    Mol.
    Sci.
    , https://doi.
    org/10.
    3390/ijms20030646[3] Zhang et al .
    , (2022).
    CAR-NK cells for cancer immunotherapy: from bench to bedside.
    Biomarker Research, https://doi.
    org/10.
    1186/s40364-022-00364-6 Disclaimer: WuXi AppTec content team focuses on global presentations Advances in Biomedical Health Research

    .

    This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
    .

    This article is also not a treatment plan recommendation
    .

    For guidance on treatment options, please visit a regular hospital
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.